Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.
Sumitomo Chemical's Q2 2025 earnings saw strong core profit growth and an optimistic FY2025 outlook despite market challenges.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈